BofA update shows where active managers are putting money
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a pharmaceutical preparations company with a market capitalization of $2.63 million, has terminated its At-the-Market Sales Agreement with WallachBeth Capital LLC, as per its recent SEC filing. This decision, effective March 18, 2025, follows the original agreement detailed in a January 6, 2025 filing.
On Monday, the company issued a notice to WallachBeth Capital, initiating the termination process, which is set to conclude ten days post-notice. The decision comes as LIXT’s stock has declined 42% year-to-date, according to InvestingPro data. Lixte Biotechnology is now considering different methods to secure additional equity capital.
The Sales Agreement was initially filed with the SEC as Exhibit 10.1 and was part of Lixte’s strategy to sell shares through WallachBeth Capital in a bid to raise capital on an ongoing basis. While InvestingPro data shows the company maintains strong liquidity with a current ratio of 5.13 and more cash than debt, the termination suggests a shift in the company’s financing strategy, although specifics about the alternatives Lixte is exploring have not been disclosed.
Lixte Biotechnology Holdings, incorporated in Delaware and based in Pasadena, California, is recognized in the industrial sector for its focus on pharmaceutical preparations. The company’s decision to end the sales agreement and look for new capital-raising avenues is a significant move, which is being watched by investors and market analysts. According to InvestingPro, the company currently trades near its Fair Value, with additional insights available to subscribers.
The information for this article is based on a press release statement.
In other recent news, Lixte Biotechnology Holdings, Inc. is facing a potential delisting from the Nasdaq Capital Market due to not meeting the minimum stockholders’ equity requirement of $2.5 million. The company has submitted a compliance plan and is awaiting a hearing before a Nasdaq Hearings Panel, which could grant an extension until August 2025. Meanwhile, Lixte has entered into a sales agreement with WallachBeth Capital, LLC to offer and sell common stock shares up to $1.7 million. This at-the-market offering will help raise capital for working capital and general corporate expenses, including the development of their lead clinical compound LB-100.
Additionally, Lixte announced the resignation of Eric Forman, Vice President and Chief Operating Officer, effective December 31, 2024, due to personal reasons. The company has not yet named a successor or provided details on the transition plan. These developments are part of Lixte’s ongoing efforts to navigate financial challenges and maintain its strategic direction. The information comes from recent press releases and filings with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.